Function Health: What They Miss

The Core Model: Lab Data Without a Treatment Layer

Function Health sells access to information. For $499 per year, members receive two rounds of blood and urine testing covering over 100 biomarkers, from lipid panels and metabolic markers to hormone levels and inflammatory indicators. Results populate a mobile dashboard with color-coded ranges and general explanations.

What the Dashboard Delivers

The interface groups results into categories (heart, metabolic, hormones, cancer screening) and flags values outside reference ranges. Members can track trends across testing cycles. The design is polished. The experience feels like a consumer product, not a clinical encounter.

Where the Model Stops

The service does not diagnose. It does not treat. There is no prescribing clinician on the other end making a therapeutic decision based on abnormal findings. A member who discovers an elevated HbA1c of 6.8% (firmly in the diabetic range per ADA diagnostic criteria) must find a separate provider to initiate metformin, order confirmatory testing, or discuss lifestyle intervention [1]. The gap between "knowing a number" and "acting on a number" is where Function Health's model breaks down most visibly.

No Prescribing Means No Closed Loop

A 2023 analysis published in JAMA Internal Medicine found that abnormal screening results without timely follow-up are associated with delayed diagnoses and worse outcomes, particularly for conditions like prediabetes and dyslipidemia [2]. The U.S. Preventive Services Task Force (USPSTF) explicitly ties screening recommendations to the availability of effective treatment, stating that "the benefits of screening depend on adequate follow-up and treatment" in its evidence framework [3].

The Follow-Up Bottleneck

Function Health's model assumes the member already has a primary care provider who will accept outside lab work, interpret it in clinical context, and initiate appropriate management. That assumption fails often. A 2022 report from the National Association of Community Health Centers estimated that roughly 100 million Americans lack a primary care physician [4]. For these members, Function Health delivers data into a vacuum.

Specialist Referral Gaps

Even members with established physicians face friction. Many PCPs are skeptical of direct-to-consumer lab panels. They may refuse to act on results they did not order, citing liability concerns and the absence of clinical context. Dr. Steven Woloshin, a physician-researcher at the Dartmouth Institute, has noted that "more testing does not equal better health when the tests are disconnected from clinical decision-making" [5].

Missing Diagnostic Modalities

Blood work captures one dimension of health. Function Health does not offer any of the diagnostic tools that longevity-focused clinicians consider standard.

No Imaging

There is no coronary artery calcium (CAC) scoring, which the 2019 ACC/AHA guidelines recommend as a tie-breaker for intermediate-risk patients considering statin therapy [6]. No DEXA scans for bone density or body composition. No carotid intima-media thickness measurements. No abdominal ultrasound for hepatic steatosis, despite MASLD affecting an estimated 30% of the global adult population according to a 2023 meta-analysis in The Lancet Gastroenterology & Hepatology [7].

No Genetic or Genomic Testing

Pharmacogenomic testing (which predicts drug metabolism through CYP450 variants) is absent. So is testing for APOE4 status, BRCA variants, MTHFR polymorphisms, or Lp(a) genetic risk. While Function Health does test serum Lp(a) levels, it cannot tell a member whether their elevated result reflects a genetically fixed trait or a modifiable factor [8].

No Functional Testing

Continuous glucose monitors, VO2 max assessments, grip strength measurements, and other functional markers that longevity medicine practitioners increasingly rely on are outside Function Health's scope. The company tests blood. That is the boundary.

The Reference Range Problem

Function Health uses what it calls "optimal ranges" rather than standard laboratory reference ranges. This distinction matters clinically.

Standard vs. "Optimal" Ranges

Standard reference ranges are derived from the central 95% of a healthy population. They are imperfect but statistically grounded. Function Health's optimal ranges are narrower. The company has not published the methodology or population data behind these thresholds in any peer-reviewed venue.

Clinical Consequences of Narrow Ranges

A tighter range flags more results as abnormal. This can generate anxiety and drive unnecessary follow-up testing. A 2020 systematic review in the BMJ found that expanded screening panels frequently produce false-positive results, leading to overdiagnosis and patient harm including invasive procedures for conditions that would never have caused symptoms [9]. The review analyzed 65 studies covering cancer, cardiovascular, and metabolic screening programs and concluded that "the probability of net harm increases as screening moves further from evidence-based guidelines."

When a member sees a testosterone level of 420 ng/dL flagged as "suboptimal" (well within the Endocrine Society's normal range of 264 to 916 ng/dL), the clinical significance depends entirely on symptoms, free testosterone, SHBG, and clinical context that a dashboard cannot provide [10].

Cost-Effectiveness Questions

At $499 per year, Function Health is less expensive than full concierge medicine programs (which typically run $2,000 to $10,000 annually) but more expensive than targeted screening through a PCP visit covered by insurance.

What Insurance Covers at No Cost

Under the Affordable Care Act, most insurance plans cover the following preventive labs at zero cost-sharing: lipid panel, HbA1c or fasting glucose (for at-risk adults), hepatitis B and C screening, HIV testing, and basic metabolic panels when ordered by a physician during a wellness visit [11]. A member paying $499 to Function Health is paying out-of-pocket for tests that overlap substantially with what their insurance already covers.

The Marginal Value Calculation

The marginal value of Function Health lies in the additional biomarkers beyond standard preventive panels: apolipoprotein B, high-sensitivity CRP, insulin, homocysteine, full thyroid panels (TSH, free T3, free T4, thyroid antibodies), sex hormones, and tumor markers. Whether these additional markers improve outcomes in asymptomatic individuals remains debated. The USPSTF does not recommend routine screening with hs-CRP, homocysteine, or tumor markers like PSA in average-risk populations due to insufficient evidence of net benefit [3].

How Function Health Compares to Alternatives

Several competitors occupy the lab-driven wellness space, each with different trade-offs.

Versus Concierge or Longevity Medicine Practices

Practices like the ones modeled on Peter Attia's "Medicine 3.0" framework bundle labs with imaging (CAC, DEXA, full-body MRI), pharmacogenomics, prescribing, and ongoing physician management. The cost is dramatically higher ($5,000 to $25,000+ per year), but the clinical loop is closed. Abnormal findings lead directly to treatment plans.

Versus InsideTracker and SiPhox Health

InsideTracker offers a similar biomarker-plus-dashboard model at comparable price points ($249 to $899 per panel) and includes algorithm-generated dietary and supplement recommendations. SiPhox Health combines blood biomarkers with at-home health metrics. Neither prescribes medications, so both share Function Health's core limitation.

Versus Traditional Primary Care

A motivated patient with a good PCP can request most of Function Health's biomarkers through standard lab orders. Insurance covers many of them. The PCP can also prescribe, refer, and coordinate care. The trade-off is that most PCPs will not order 100+ biomarkers on an asymptomatic patient, and appointment time for reviewing results is limited (the average U.S. Primary care visit lasts 18 minutes, according to a 2021 analysis in the Annals of Internal Medicine) [12].

Legitimate Strengths Worth Acknowledging

Function Health is not without value. Three aspects of the model deserve recognition.

Accessibility of Advanced Biomarkers

Ordering apolipoprotein B, fasting insulin, or a full thyroid panel through traditional channels requires a physician willing to order them and an insurer willing to cover them. Many PCPs default to standard lipid panels and basic metabolic panels. Function Health removes that gatekeeping friction for patients who want deeper data.

Longitudinal Tracking

Twice-yearly testing creates trend data. A single fasting glucose of 105 mg/dL is ambiguous. Three consecutive readings trending from 95 to 105 to 112 over 18 months tells a clear story of metabolic deterioration. Function Health's dashboard visualizes these trends effectively.

Patient Activation

Research published in Health Affairs demonstrates that patients who access their own lab results show higher rates of engagement with preventive care and follow-up appointments [13]. Function Health may serve as an entry point that drives some members toward more comprehensive clinical relationships they otherwise would not have pursued.

Who Should (and Should Not) Use Function Health

The service fits best for health-literate individuals who already have a primary care relationship and want supplementary data between annual visits. It is a monitoring layer, not a medical home.

Poor Fit Scenarios

Members without an existing physician, members with known chronic conditions requiring medication management, and members prone to health anxiety from ambiguous lab values are likely to experience more harm than benefit. The absence of clinical interpretation turns every borderline result into an unanswered question.

Better Fit Scenarios

A 38-year-old with a family history of cardiovascular disease, an established cardiologist, and a desire to track apoB and Lp(a) trends between annual visits may extract genuine value. The key variable is whether the member has somewhere to take abnormal results.

The Bottom Line on Clinical Gaps

Function Health sells the first half of medicine (measurement) without the second half (management). That asymmetry is the company's defining limitation. Lab values without clinical context, prescribing authority, imaging, genetic data, or coordinated follow-up leave members with information they may not be equipped to use. The 2024 Endocrine Society clinical practice guideline on testosterone therapy states that "diagnosis of hypogonadism requires both biochemical confirmation and clinical signs and symptoms," a standard that no dashboard alone can meet [10]. Members considering Function Health should budget not just $499 for the service, but the time and cost of a clinician who can translate those numbers into action.